US ultra-rare disease specialist Ultragenyx Pharmaceutical (Nasdaq: RARE) and gene and cell therapy company Abeona Therapeutics (Nasdaq: ABEO) have announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA).
Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program. Also, following regulatory approval, Abeona is eligible to receive tiered royalties from mid-single-digit up to 10% on net sales and up to $30.0 million in commercial milestone payments.
Shares of both companies dipped on the news, with Abeona closing down 2.8% on Tuesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze